Expertise in
6
conditions

Nong S. Xu

No. 79 Qingchun Road, 
Hangzhou, CN 
Expertise in
6
conditions
No. 79 Qingchun Road, 
Hangzhou, CN 

Overview

Nong Xu practices practicing medicine in Hangzhou, China.

Mr. Xu is highly rated in 6 conditions, according to our data. His clinical expertise encompasses Stomach Cancer, Gastroesophageal Junction Cancer, Agranulocytosis, Esophageal Cancer, and Gastrectomy.

He is actively involved in clinical research, co-authoring 179 peer reviewed articles and participating in 6 clinical trials.

Gender

Male

Locations

No. 79 Qingchun Road, Hangzhou, 310003, China
Other Locations
No. 79, 86 Qingchun Road, Hangzhou, 310003, China

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

6 Clinical Trials

A Randomized, Double-blind, Multicenter, Phase III Study Comparing the Efficacy and Safety of AK104 Plus Oxaliplatin and Capecitabine (XELOX) Versus Placebo Plus XELOX as First-line Treatment for Locally Advanced Unresectable or G/GEJ Adenocarcinoma
A Randomized, Double-blind, Multicenter, Phase III Study Comparing the Efficacy and Safety of AK104 Plus Oxaliplatin and Capecitabine (XELOX) Versus Placebo Plus XELOX as First-line Treatment for Locally Advanced Unresectable or G/GEJ Adenocarcinoma
Enrollment Status: Completed
Publish Date: November 19, 2025
Intervention Type: Drug
Study Drug: AK104
Study Phase: Phase 3
A Multicenter, Open-label, Phase Ib/II Study to Evaluate the Efficacy and Safety of Anti-PD-1 Antibody AK105 in Patients With Selected Advanced Solid Tumors
A Multicenter, Open-label, Phase Ib/II Study to Evaluate the Efficacy and Safety of Anti-PD-1 Antibody AK105 in Patients With Selected Advanced Solid Tumors
Enrollment Status: Completed
Publish Date: March 12, 2025
Intervention Type: Drug
Study Phase: Phase 1/Phase 2
A Phase 2, Multi-Cohort Study to Investigate the Safety, Pharmacokinetics and Preliminary Antitumor Activity of the Anti-PD-1 Monoclonal Antibody BGB A317 in Combination With Chemotherapy as First-Line Treatment in Adults With Inoperable, Locally Advanced or Metastatic Esophageal, Gastric, or Gastroesophageal Junction Carcinoma
A Phase 2, Multi-Cohort Study to Investigate the Safety, Pharmacokinetics and Preliminary Antitumor Activity of the Anti-PD-1 Monoclonal Antibody BGB A317 in Combination With Chemotherapy as First-Line Treatment in Adults With Inoperable, Locally Advanced or Metastatic Esophageal, Gastric, or Gastroesophageal Junction Carcinoma
Enrollment Status: Completed
Publish Date: October 23, 2024
Intervention Type: Drug
Study Phase: Phase 2
A Multi-center, Phase II Study to Evaluate Safety and Efficacy of Adjuvant Chemotherapy With Tegafur Gimeracil Oteracil Potassium Capsule Plus Oxaliplatin and Camrelizumab for Stage III Gastric Cancer (FOCUS-02)
A Multi-center, Phase II Study to Evaluate Safety and Efficacy of Adjuvant Chemotherapy With Tegafur Gimeracil Oteracil Potassium Capsule Plus Oxaliplatin and Camrelizumab for Stage III Gastric Cancer (FOCUS-02)
Enrollment Status: Active_not_recruiting
Publish Date: September 19, 2024
Intervention Type: Drug
Study Drugs: Camrelizumab, Oxaliplatin, Tegafur gimeracil oteracil potassium
Study Phase: Phase 2
A Prospective, Randomized, Controlled, Double-blind, Multi-center Clinical Study of Nimotuzumab Combinated With Gemcitabine Contrast to Placebo Combinated With Gemcitabine in K-RAS Wild-type,Locally Advanced and Metastatic Pancreatic Cancer
A Prospective, Randomized, Controlled, Double-blind, Multi-center Clinical Study of Nimotuzumab Combinated With Gemcitabine Contrast to Placebo Combinated With Gemcitabine in K-RAS Wild-type,Locally Advanced and Metastatic Pancreatic Cancer
Enrollment Status: Completed
Publish Date: April 04, 2024
Intervention Type: Drug, Other
Study Drugs: Nimotuzumab, Gemcitabine
Study Phase: Phase 3
A Multi-Center, Open Label Phase Ib/II Clinical Study to Evaluate JS001 in Patients With Advanced Gastric Adenocarcinoma, Esophageal Squamous Cell Carcinoma, Nasopharyngeal Carcinoma and Head and Neck Squamous Cell Carcinoma
A Multi-Center, Open Label Phase Ib/II Clinical Study to Evaluate JS001 in Patients With Advanced Gastric Adenocarcinoma, Esophageal Squamous Cell Carcinoma, Nasopharyngeal Carcinoma and Head and Neck Squamous Cell Carcinoma
Enrollment Status: Unknown
Publish Date: December 13, 2021
Intervention Type: Biological
Study Drug: JS001 Anti-PD-1 Antibody
Study Phase: Phase 1/Phase 2
View 5 Less Clinical Trials

179 Total Publications

Camrelizumab plus CAPOX with camrelizumab based maintenance versus CAPOX alone as initial treatment for gastric or gastro-oesophageal junction adenocarcinoma: randomised phase 3 trial.
Camrelizumab plus CAPOX with camrelizumab based maintenance versus CAPOX alone as initial treatment for gastric or gastro-oesophageal junction adenocarcinoma: randomised phase 3 trial.
Journal: BMJ (Clinical research ed.)
Published: March 12, 2026

Frequently Asked Questions about Nong S. Xu

Is Nong S. Xu a top-rated expert for Stomach Cancer?

MediFind is an objective health platform that identifies experts based on real-world data. Nong S. Xu is classified as an Advanced expert for Stomach Cancer, meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

Does Nong S. Xu participate in research or clinical trials?

Yes. Nong S. Xu has published 179 articles and abstracts on conditions like Stomach Cancer. You can view a list of Nong S. Xu's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Mr. Xu's expertise for a condition
ConditionClose
      View All 23 Experienced Conditions
      Want to save this expert for later?
      Sign Up
      Not sure about your diagnosis?
      Check Your Symptoms
       
       
       
       
      Learn about our expert tiers
      Learn More
      Are you the provider on this profile?
      Claim Profile